Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

被引：0
|
作者：
Viale, G [1 ]
Regan, M [1 ]
Dell'Orto, P [1 ]
Del Curto, B [1 ]
Braye, S [1 ]
Orosz, Z [1 ]
Brown, R [1 ]
Olszewski, WP [1 ]
Knox, F [1 ]
Oehlschlegel, C [1 ]
Thürlimann, B [1 ]
机构：
[1] BIG 1 98 Collaborat Int Breast Canc Study Grp, Bern, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S14
页数：2
相关论文
共 50 条
  • [41] Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.
    Ribi, K.
    Aldridge, J.
    Phillips, K.
    Sun, Z.
    Thompson, A. M.
    Harvey, V. J.
    Thuerlimann, B.
    Cardoso, F.
    Coates, A. S.
    Bernhard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopausal women with estrogen receptor-positive breast cancer
    Viale, G.
    Giobbie-Hurder, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S17 - S17
  • [43] Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
    Leone, Jose P.
    Cole, Bernard F.
    Regan, Meredith M.
    Thurlimann, Beat
    Coates, Alan S.
    Rabaglio, Manuela
    Giobbie-Hurder, Anita
    Gelber, Richard D.
    Ejlertsen, Bent
    Harvey, Vernon J.
    Neven, Patrick
    Lang, Istvan
    Bonnefoi, Herve
    Wardley, Andrew
    Goldhirsch, Aron
    Di Leo, Angelo
    Colleoni, Marco
    Vaz-Luis, Ines
    Lin, Nancy U.
    CANCER, 2021, 127 (05) : 700 - 708
  • [44] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jon
    Sofrygin, Oleg
    Thomas, Simu K.
    Papo, Natalie L.
    Barghout, Victoria
    CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
  • [45] Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer:: the Belgian perspective
    Kannon, J.
    Berliere, M.
    Depypere, H.
    Dirix, L.
    Jerusalem, G.
    Neven, P.
    Pandaens, R.
    Lecomte, P.
    BREAST, 2007, 16 : S64 - S65
  • [46] Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
    Rabaglio, M.
    Sun, Z.
    Price, K. N.
    Castiglione-Gertsch, M.
    Hawle, H.
    Thurlimann, B.
    Mouridsen, H.
    Campone, M.
    Forbes, J. F.
    Paridaens, R. J.
    Colleoni, M.
    Pienkowski, T.
    Nogaret, J. -M.
    Lang, I.
    Smith, I.
    Gelber, R. D.
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2009, 20 (09) : 1489 - 1498
  • [47] THE USE OF ADJUVANT ENDOCRINE THERAPY IN OLDER WOMEN WITH ESTROGEN RECEPTOR-POSITIVE (ER plus ) BREAST CANCER (BC)
    Aapro, M.
    Crivellari, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 208 - 209
  • [48] Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer:: supplementary results from the BIG 1-98 randomised trial
    Rasmussen, Birgitte B.
    Regan, Meredith M.
    Lykkesfeldt, Anne E.
    Dell'Orto, Patrizia
    Del Curto, Barbara
    Henriksen, Katrine L.
    Mastropasqua, Mauro G.
    Price, Karen N.
    Mery, Eliane
    Lacroix-Triki, Magali
    Braye, Stephen
    Altermatt, Hans J.
    Gelber, Richard D.
    Castiglione-Gertsch, Monica
    Goldhirsch, Aron
    Gusterson, Barry A.
    Thurlimann, Beat
    Coates, Alan S.
    Viale, Giuseppe
    LANCET ONCOLOGY, 2008, 9 (01): : 23 - 28
  • [49] Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
    Viale, Giuseppe
    Regan, Meredith M.
    Maiorano, Eugenio
    Mastropasqua, Mauro G.
    Dell'Orto, Patrizia
    Rasmussen, Birgitte Bruun
    Raffoul, Johnny
    Neven, Patrick
    Orosz, Zsolt
    Braye, Stephen
    Oehlschlegel, Christian
    Thuerlimann, Beat
    Gelber, Richard D.
    Castiglione-Gertsch, Monica
    Price, Karen N.
    Goldhirsch, Aron
    Gusterson, Barry A.
    Coates, Alan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3846 - 3852
  • [50] COST-EFFECTIVENESS ASSESSMENT FOR COLOMBIA OF LETROZOLE VS. TAMOXIFEN IN ADJUVANT TREATMENT OF HORMONE RECEPTOR-POSITIVE, POST-MENOPAUSAL EARLY BREAST CANCER WOMEN
    Gamboa, O.
    Chicaiza, L.
    Garcia, M.
    VALUE IN HEALTH, 2009, 12 (07) : A496 - A496
12345